Copertina

HiDAC Consolidation in AML : Comparable Outcomes With Reduced Toxicity Using a Three‐Day Schedule ( HiDAC ‐123)

Fuente: Wiley Open Access

Salvato in:

Dettagli Bibliografici
Autori principali:	Baher Krayem, Nurit Horesh, Avraham Frisch, Tsila Zuckerman, Yishai Ofran
Natura:	Artículo Open Access
Pubblicazione:	Wiley 2025
Soggetti:	European Journal of Haematology
Accesso online:	Acceder al recurso
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!

Documenti analoghi

Comparison of HiDAC Versus FLAG‐IDA in the Treatment of Relapsed Acute Myeloid Leukemia and High‐Risk Myelodysplastic Syndrome
di: Man Wai Tang, et al.
Pubblicazione: (2024)

Post‐Relapse Outcomes of Older Patients With NPM1‐Mutated AML Are Favorable With Allo Transplant in Second Remission
di: Avraham Frisch, et al.
Pubblicazione: (2024)

CPX‐351 +/− gemtuzumab ozogamicin as induction therapy for adult patients with newly diagnosed, favourable‐intermediate risk, FLT3‐ITD negative, AML: A pilot study
di: Chezi Ganzel, et al.
Pubblicazione: (2024)

Unveiling the Genetic and Clinical Differences of Acute Myeloid Leukemia (AML) in Obese Patients
di: Fevzi F. Yalniz, et al.
Pubblicazione: (2024)

Evolution from an antecedent chronic myeloid malignancy does not impact survival outcomes in NPM1‐mutated AML
di: Elliot Smith, et al.
Pubblicazione: (2024)

Feasibility, accuracy, and usability analysis of MapAML, a first‐in‐class app for integrated diagnosis in acute myeloid leukemia
di: Thaís B. Moyen, et al.
Pubblicazione: (2024)

Medical and Nutritional Outcomes Are Similar Among Autologous Transplant Patients on Enteral Nutrition When Compared to Parenteral Nutrition. A Randomized Pilot Study
di: Janet Madill, et al.
Pubblicazione: (2025)

Outcomes After Allogeneic Hematopoietic Cell Transplantation in Adults With Myelodysplastic Syndrome With 65 Years or Older Compared to Youngers. A Retrospective Analysis of the Latin America Registry
di: Fernando Barroso Duarte, et al.
Pubblicazione: (2025)

Duration of anti‐CD20 monoclonal antibody maintenance positively correlates with clinical outcomes in follicular lymphoma patients, supporting adherence to the recommended 2‐year maintenance paradigm
di: Michal Nordkin, et al.
Pubblicazione: (2025)

Late Immune Effector Cell‐Associated Hematologic Toxicity After CD19 CAR ‐T Therapy: Incidence, Clinical Course, and Resource Utilization
di: Philippe Giguère, et al.
Pubblicazione: (2026)

Genomic Landscape and Clinical Outcomes of Advanced Pediatric Myelodysplastic Syndromes
di: Chenmeng Liu, et al.
Pubblicazione: (2026)

Intravascular Large B‐Cell Lymphoma: Clinicopathological Characteristics and Outcomes
di: Carmen Rodríguez García, et al.
Pubblicazione: (2026)

Outcomes of Melflufen Treatment in Patients With Relapsed/Refractory Multiple Myeloma
di: Shahrier Hossain, et al.
Pubblicazione: (2025)

Reduced Intensity Conditioning Prior Autologous Stem Cell Transplantation in Elderly DLBCL Patients
di: Tim Strüßmann, et al.
Pubblicazione: (2024)

Reduced‐ Versus Extended‐Dose Anticoagulation for Venous Thromboembolism in Patients With and Without Cancer: A Systematic Review and Meta‐Analysis
di: Muhammad Faizan Ali, et al.
Pubblicazione: (2026)

Maternal and Fetal Outcomes of Aplastic Anemia During Pregnancy and Delivery: Systematic Review and Meta‐Analysis
di: Aashima Arora, et al.
Pubblicazione: (2024)

Outcomes of Elderly Patients Admitted to the Intensive Care Unit for Newly Diagnosed Acute Myeloid Leukemia
di: Guillaume Berton, et al.
Pubblicazione: (2025)

Outcomes with ibrutinib in patients with chronic lymphocytic leukaemia: Results from the German multicentre REALITY study
di: Anke Gerhardt, et al.
Pubblicazione: (2024)

Standard Versus Reduced‐Doses of Post‐Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation
di: Sara Redondo, et al.
Pubblicazione: (2025)

Improved Outcomes of Myeloma Cast Nephropathy in Newly Diagnosed Multiple Myeloma With Modern Anti‐Myeloma Therapies
di: Michael Sang Hughes, et al.
Pubblicazione: (2025)

Outcomes of older adults undergoing allogeneic hematopoietic cell transplantation with post‐transplant cyclophosphamide based prophylaxis
di: Victoria Murillo, et al.
Pubblicazione: (2024)

Predictive and Prognostic Significance of Patient‐Reported Outcomes for Survival and Adverse Events in Daratumumab‐Treated Multiple Myeloma
di: Ahmad Y. Abuhelwa, et al.
Pubblicazione: (2025)

Significance of Pre‐ and Posttransplant Minimal Residual Disease on Transplant Outcomes in Core‐Binding Factor Acute Myeloid Leukemia
di: Chika Tokuda, et al.
Pubblicazione: (2025)

Steroid Responsiveness and Clinical Outcomes in Diamond–Blackfan Anemia: Analysis From the Canadian Inherited Marrow Failure Registry
di: Young Bae Choi, et al.
Pubblicazione: (2026)

Transition Into Clinical Routine and Survival Outcomes of BCL2 ‐ and BTK Inhibitors: An Analysis of Patient Data From the GCLLSG Registry
di: Nadine Kutsch, et al.
Pubblicazione: (2026)

Treatment‐Free Remission Outcomes in a BCR::ABL1 Digital PCR Selected Clinical Cohort of CML Patients
di: C. Kockerols, et al.
Pubblicazione: (2025)

Anchored Indirect Treatment Comparison Finds Comparable Effects of Pegcetacoplan and Iptacopan in Paroxysmal Nocturnal Haemoglobinuria
di: Regis Peffault de Latour, et al.
Pubblicazione: (2025)

Comparing Human‐Level and Machine Learning Model Performance in White Blood Cell Morphology Assessment
di: Patrick Lawrence, et al.
Pubblicazione: (2024)

Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Receiving On‐Demand Recombinant von Willebrand Factor in the United Kingdom
di: Mike Laffan, et al.
Pubblicazione: (2025)

Systematic review of hematopoietic stem cell gene therapy approach in thalassemia: Comparative analysis in animal models
di: Indira Laksmi Maharani, et al.
Pubblicazione: (2024)

Relationship Between Daily Step Count, Biological Markers, and Clinical Outcomes in Patients With Sickle Cell Anemia: A Cross‐Sectional Study
di: Mor Diaw, et al.
Pubblicazione: (2026)

Patient‐Reported Outcomes With Luspatercept Through 5 Years of Treatment in Patients With Non‐Transfusion‐Dependent β‐Thalassemia Treated in the BEYOND Trial
di: Khaled M. Musallam, et al.
Pubblicazione: (2026)

Outcomes and Healthcare Resource Utilisation in Adults With von Willebrand Disease Treated With Recombinant von Willebrand Factor in Surgical Settings in the United Kingdom
di: Mike Laffan, et al.
Pubblicazione: (2025)

Allogeneic Haematopoietic Stem Cell Transplantation Using Reduced‐Intensity Fludarabine, Busulfan and Anti‐T‐Lymphocyte Globulin With Strategic Donor Lymphocyte Infusion in Older Patients With Myeloid Malignancy
di: Chris Armstrong, et al.
Pubblicazione: (2025)

Comparative Effectiveness and Safety of PI‐Rd Triplets in Relapsed/Refractory Multiple Myeloma: INSIGHT‐MM Data Analysis
di: Noemi Puig, et al.
Pubblicazione: (2026)

Evolving Patterns of EBV ‐Associated PTLD After Allogeneic Stem Cell Transplantation: Frequency, Characteristics and Outcomes in a Multicenter GETH ‐ TC Study
di: Irene García‐Cadenas, et al.
Pubblicazione: (2026)

Hyper‐CVAD and Modified CALGB‐10403 Regimens in Adult Patients With Philadelphia‐Negative Acute Lymphoblastic Leukemia: A Comparative Study
di: Jessica Zalapa‐Soto, et al.
Pubblicazione: (2025)

Outcomes with low dose anti‐thymocyte globulin based graft versus host disease prophylaxis after mismatched unrelated donor allogeneic hematopoietic cell transplantation
di: Hafsah Chalchal, et al.
Pubblicazione: (2024)

Biological Findings and Clinical Outcomes in Patients Treated With R‐CHOP Plus High‐Dose Methotrexate as First‐Line Therapy in Large B‐Cell Lymphoma With Testis Involvement
di: R. Liévin, et al.
Pubblicazione: (2024)

Sustained Improvement in Health‐Related Quality of Life in Transplant‐Ineligible Newly Diagnosed Multiple Myeloma Treated With Daratumumab, Lenalidomide, and Dexamethasone: MAIA Final Analysis of Patient‐Reported Outcomes
di: Aurore Perrot, et al.
Pubblicazione: (2025)